Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug?

Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug?

On Tuesday, Biogen Inc. (NASDAQ:BIIB) shares fell slightly, extending the current monthly declines closer to 14%. The biotechnology company lost an appeal on its multiple sclerosis drug, Tecfidera, with the US Court of Appeals for the Federal Circuits upholding the decision made by a trial court. Biogen shares are also experiencing pressure from another report
The post Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug? appeared first on Invezz.